11 research outputs found
Influence of key polymer attributes, manufacturing conditions and sintering on abuse deterrence of physical barrier type abuse deterrent formulations (ADF)
When sintering us used to treat tablet formulations containing polyethylene oxide (PEO), the polymer particles are able to form stronger bonds thereby increase tablet tensile strength. This increase in strength can make it more difficult for an abuser to break, chew, or grind opioid tablets. A mechanistic study was implemented to understand the key sintering factors that influence tensile strength
Physical Barrier Type Abuse-Deterrent Formulations: Mechanistic Understanding of Sintering-Induced Microstructural Changes in Polyethylene Oxide Placebo Tablets
The main goal of the presented work was to understand changes in the microstructure of tablets, as well as the properties of its main component viz. polyethylene oxide (PEO) as a function of sintering. Key polymer variables and sintering conditions were investigated, and sintering-induced increase in tablet tensile strength was evaluated. For the current study, binary-component placebo tablets comprised of varying ratios of PEO and anhydrous dibasic calcium phosphate (DCP) were prepared at two levels of tablet solid fraction. The prepared tablets were sintered in an oven at 80°C at different time points ranging from 10 to 900 min and were evaluated for pore size, tablet expansion (%), and PEO crystallinity. The results showed that for efficient sintering and a significant increase in the tablet tensile strength, a minimum of 50% w/w PEO was required. Moreover, all microstructural changes in tablets were found to occur within 60 min of sintering, with no significant changes occurring thereafter. Sintering also resulted in a decrease in PEO crystallinity, causing changes in polymer ductility. These changes in PEO ductility resulted in tablets with higher tensile strength. Formulation variables such as PEO level and PEO particle size distribution were found to be important influencers of the sintering process. Additionally, tablets with high initial solid fraction and sintering duration of 60 min were found to be optimal conditions for efficient sintering of PEO-based compacts. Finally, prolonged sintering times were not found to provide any additional benefits in terms of abuse-deterrent properties
Influence of key polymer attributes, manufacturing conditions and sintering on abuse deterrence of physical barrier type abuse deterrent formulations (ADF)
When sintering us used to treat tablet formulations containing polyethylene oxide (PEO), the polymer particles are able to form stronger bonds thereby increase tablet tensile strength. This increase in strength can make it more difficult for an abuser to break, chew, or grind opioid tablets. A mechanistic study was implemented to understand the key sintering factors that influence tensile strength
Synthesis and Biological Evaluation of a Biotinylated Paclitaxel with an Extra-Long Chain Spacer Arm
A biotinylated paclitaxel derivative with an extra-long
chain (LC-LC-biotin)
spacer arm was synthesized using an improved synthetic reaction sequence.
The biotinylated paclitaxel analogue retained excellent microtubule
stabilizing activity in vitro. Furthermore, it was shown that this
analogue can simultaneously engage streptavidin and the binding site
on microtubules, making it suitable for localization studies or for
the attachment of paclitaxel to solid substrates via a streptavidin
linkage
Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts
A disodium phosphonooxymethyl
prodrug of the antitumor agent triptolide
was prepared from the natural product in three steps (39% yield) and
displayed excellent aqueous solubility at pH 7.4 (61 mg/mL) compared
to the natural product (17 μg/mL). The estimated shelf life
(<i>t</i><sub>90</sub>) for hydrolysis of the prodrug at
4 °C and pH 7.4 was found to be two years. In a mouse model of
human colon adenocarcinoma (HT-29), the prodrug administered intraperitoneally
was effective in reducing or eliminating xenograft tumors at dose
levels as low as 0.3 mg/kg when given daily and at 0.9 mg/kg when
given less frequently. When given via intraperitoneal and oral routes
at daily doses of 0.6 and 0.9 mg/kg, the prodrug was also effective
and well tolerated in a mouse model of human ovarian cancer (A2780)